abstract |
A method for the treatment of conditions including ophthalmic symptoms, stress-related conditions, and neurodegenerative conditions in mammals is provided. A first component containing a compound that results in direct or indirect activation of an α2 adrenergic receptor and a second component containing an α1 adrenergic receptor antagonist are co-administered. [Selection figure] None |